Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

Abstract

Our findings indicate that tofacitinib and baricitinib had comparable continuing efficacies and safety profiles. However, there is a possibility that the influence of clinical characteristics on the treatment response differs. The comparison provides useful information to the optimal use of JAK inhibitors in real-world settings.